APA

Bylicki O., Ferlay C., Chouaid C., Lavolé A., Barlési F., Dubos C., Westeel V., Créquit J., Corre R., Vergnenègre A., Monnet I., Le Caer H., Fournel P., Vaylet F., Falchero L., Poudenx M., Linard P., Pérol D., Zalcman G. & Pérol M. (20140123). Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chicago

Bylicki Olivier, Ferlay Céline, Chouaid Christos, Lavolé Armelle, Barlési Fabrice, Dubos Cathérine, Westeel Virginie, Créquit Jacky, Corre Roman, Vergnenègre Alain, Monnet Isabelle, Le Caer Hervé, Fournel Pierre, Vaylet Fabien, Falchero Lionel, Poudenx Michel, Linard Pauline, Pérol David, Zalcman Gérald and Pérol Maurice. 20140123. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Harvard

Bylicki O., Ferlay C., Chouaid C., Lavolé A., Barlési F., Dubos C., Westeel V., Créquit J., Corre R., Vergnenègre A., Monnet I., Le Caer H., Fournel P., Vaylet F., Falchero L., Poudenx M., Linard P., Pérol D., Zalcman G. and Pérol M. (20140123). Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MLA

Bylicki Olivier, Ferlay Céline, Chouaid Christos, Lavolé Armelle, Barlési Fabrice, Dubos Cathérine, Westeel Virginie, Créquit Jacky, Corre Roman, Vergnenègre Alain, Monnet Isabelle, Le Caer Hervé, Fournel Pierre, Vaylet Fabien, Falchero Lionel, Poudenx Michel, Linard Pauline, Pérol David, Zalcman Gérald and Pérol Maurice. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. : Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 20140123.